According to the Zhitong Finance App, Weitai Medical-B (02235) announced 2026 interim results, with operating income of 414 million yuan, up 68.4% year on year; gross profit of 239 million yuan, up 88.1% year on year; profit attributable to parent company owners of 40.2732 million yuan, turning a year-on-year loss into a profit; profit per share of 0.1 yuan.

According to the announcement, the significant increase in revenue is mainly due to continued rapid growth in domestic and international sales of glucose monitoring systems, and a significant increase in sales of insulin pump systems in the international market.

Net profit turned a loss into a profit, mainly due to a sharp rise in operating income, a significant expansion in gross profit scale, and continuous optimization of the superimposed expense ratio.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.